Abstract
A growing number of dominantly inherited neurodegenerative disorders are associated with an expanded polyglutamine-encoding sequence. Alterations in gene expression have been described for several of these diseases. Many animal and cell culture models have been established. In order to generate gene expression profiles of model systems using microarray technology, the Hereditary Disease Array Group (HDAG) was formed. This collaboration helps participants to refine the design, methods, and analyses and to identify potential problem areas. The ultimate goal of HDAG is to elucidate the mechanisms by which expanded polyglutamine tracts contribute to neuropathogenesis. This conference review intends to describe this collaborative effort and highlight some of the issues relating to technical aspects, quality control and bioinformatics as well as therapeutic targets and human samples.
Keywords: Hereditary disease array group hdag microarrays, neurodegenerative disorders, polyglutamine-encoding, hintington disease, huntington disease, spinocerebellar ataxias, spinobulbar muscular atrophy drpla, gene expression, bioinformatics, target validation, disease markers
Current Genomics
Title: The Hereditary Disease Array Group (HDAG) - Microarrays, Models and Mechanisms : A Collaboration Update
Volume: 2 Issue: 3
Author(s): Tim- Rasmus Kiehl, James M. Olson and Stefan M. Pulst
Affiliation:
Keywords: Hereditary disease array group hdag microarrays, neurodegenerative disorders, polyglutamine-encoding, hintington disease, huntington disease, spinocerebellar ataxias, spinobulbar muscular atrophy drpla, gene expression, bioinformatics, target validation, disease markers
Abstract: A growing number of dominantly inherited neurodegenerative disorders are associated with an expanded polyglutamine-encoding sequence. Alterations in gene expression have been described for several of these diseases. Many animal and cell culture models have been established. In order to generate gene expression profiles of model systems using microarray technology, the Hereditary Disease Array Group (HDAG) was formed. This collaboration helps participants to refine the design, methods, and analyses and to identify potential problem areas. The ultimate goal of HDAG is to elucidate the mechanisms by which expanded polyglutamine tracts contribute to neuropathogenesis. This conference review intends to describe this collaborative effort and highlight some of the issues relating to technical aspects, quality control and bioinformatics as well as therapeutic targets and human samples.
Export Options
About this article
Cite this article as:
Kiehl Rasmus Tim-, Olson M. James and Pulst M. Stefan, The Hereditary Disease Array Group (HDAG) - Microarrays, Models and Mechanisms : A Collaboration Update, Current Genomics 2001; 2 (3) . https://dx.doi.org/10.2174/1389202013350878
DOI https://dx.doi.org/10.2174/1389202013350878 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Genomic Insights into Oncology: Harnessing Machine Learning for Breakthroughs in Cancer Genomics.
This special issue aims to explore the cutting-edge intersection of genomics and oncology, with a strong emphasis on original data and experimental validation. While maintaining the focus on how machine learning and advanced data analysis techniques are revolutionizing our understanding and treatment of cancer, this issue will prioritize contributions that ...read more
Integrating Artificial Intelligence and Omics Approaches in Complex Diseases
Recent advancements in AI and omics methodologies have revolutionized the landscape of biomedical research, enabling us to extract valuable information from vast amounts of complex data. By combining AI algorithms with omics technologies such as genomics, proteomics, metabolomics, and transcriptomics, researchers can obtain a more comprehensive and multi-dimensional analysis of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nicotinic Receptors in Neurodegeneration
Current Neuropharmacology Focus on the Different Projects of Telemedicine Centered on the Elderly In France
Current Aging Science Global Expression Studies of Schizophrenic Brain: A Meta-Analysis Study Linking Neurological Immune System with Psychological Disorders
CNS & Neurological Disorders - Drug Targets Putting Huntingtin “Aggregation” in View with Windows into the Cellular Milieu
Current Topics in Medicinal Chemistry Comparative Pharmacokinetics and Metabolism Studies in Lean and Diet- Induced Obese Mice: An Animal Efficacy Model for 11β -Hydroxysteroid Dehydrogenase Type 1 (11β -HSD1) Inhibitors
Drug Metabolism Letters DNA Vaccine and the CNS Axonal Regeneration
Current Pharmaceutical Design An Update on Peptide Drugs for Voltage-Gated Calcium Channels
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [Hot Topic: Galectin-1 as an Essential Factor in Nervous System (Guest Editor: Hidenori Horie)]
Current Drug Targets Anti-Inflammatory Drugs in the Treatment of Neurodegenerative Diseases: Current State
Current Pharmaceutical Design Genetics of Congenital Heart Disease
Current Cardiology Reviews The Putative Use of Lithium in Alzheimer’s Disease
Current Alzheimer Research Glutamatergic Targets for Enhancing Extinction Learning in Drug Addiction
Current Neuropharmacology Lemongrass Extract Alleviates Oxidative Stress and Delayed the Loss of Climbing Ability in Transgenic <i>Drosophila</i> Model of Parkinson’s Disease
Letters in Drug Design & Discovery Theoretical Approaches to Protein Aggregation
Protein & Peptide Letters Glaucoma: Validated and Facile In Vivo Experimental Models of a Chronic Neurodegenerative Disease for Drug Development
Current Medicinal Chemistry - Central Nervous System Agents Sensing, Transport and Other Potential Biomedical Applications of Pseudopeptides
Current Medicinal Chemistry Clinical Application and Synthesis Methods of Deuterated Drugs
Current Medicinal Chemistry Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases
Current Neuropharmacology Depletion of Hypocretin/Orexin Neurons Increases Cell Proliferation in the Adult Subventricular Zone
CNS & Neurological Disorders - Drug Targets The Zebrafish Model as a New Discovery Path for Medicinal Plants in the Treatment of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets